Can smarter imaging make ultrasound therapy for tremors more precise?

NCT ID NCT03935581

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether a new auto-focusing imaging feature on the ExAblate Neuro system can safely guide focused ultrasound to treat essential tremor that has not responded to medication. Researchers will enroll about 20 adults with medication-resistant essential tremor and check for any device-related side effects. The goal is to see if this imaging approach is safe and feasible for targeting the brain area that causes tremors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ExAblate Neuro system with Auto-Focusing echo imaging, a device that uses focused ultrasound to treat tremor
What this could lead to
If it works, this imaging technique could make focused ultrasound treatment for essential tremor safer and more precise, potentially easing tremors without surgery.
What could go wrong
This is a small early feasibility study with only 20 participants, so results may not apply broadly. The procedure carries risks of device-related side effects, and the imaging approach may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Apr 2019

Finished

Apr 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or Female age 22 years or older 2. Able and willing to give consent and able to attend all study visits 3. A confirmed diagnosis of Essential Tremor resistant to medication therapy 4. Able to fit into MRI unit 5. Able to tolerate the procedure with or without some form of sedation 6. Able to communicate sensations during the ExAblate MRgFUS procedure 7. Able to activate Stop Sonication button during the ExAblate MRgFUS procedure Exclusion Criteria: 1. Presence of unknown or MRI unsafe devices anywhere in the body. 2. Patients with known intolerance or allergies to the MRI contrast agents 3. Women who are pregnant 4. Patients with advanced kidney disease or on dialysis 5. Significant cardiac disease or unstable hemodynamic status 6. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse 7. History of a bleeding disorder 8. Patients receiving anticoagulant or drugs known to increase risk of hemorrhage 9. Patients with cerebrovascular disease 10. Patients with brain tumors 11. Individuals who are not able or unwilling to tolerate the required prolonged stationary position during treatment (approximately 2-3 hours) 12. Patients who are currently participating in another clinical investigation 13. Patients unable to communicate with the investigator and staff 14. Patients who have cardiac shunts 15. Patients with relative contraindications to Definity ultrasound contrast agent including subjects with a family or personal history of arrhythmia's 16. Patients with chronic pulmonary disorders 17. Patients with a history of drug allergies, uncontrolled asthma or hay fever 18. Patients who have had deep brain stimulation or a prior neuroablative procedure 19. Women who are pregnant or nursing 20. Patients who have been administered botulinum toxins into the arm, neck, or face for 5 months prior to enrollment in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurologic manifestations are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential tremor Neurologic Manifestations Tremor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sunnybrook

    Toronto, Ontario, M4N 3M5, Canada

  • Yonsei University Health System, Severance Hospital

    Seoul, Seodaemun-gu, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.